<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04582110</url>
  </required_header>
  <id_info>
    <org_study_id>1002/19</org_study_id>
    <nct_id>NCT04582110</nct_id>
  </id_info>
  <brief_title>The Role of OCTA in Patients Affected by Beta Thalassemia</brief_title>
  <official_title>Retinal and Choriocapillaris Vascular Features in Patients With Beta Thalassemia by Means of Optical Coherence Tomography Angiography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federico II University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federico II University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate, using optical coherence tomography angiography (OCTA), the retinal and&#xD;
      choriocapillaris vascular features in patients affected by Beta Thalassemia. Moreover we&#xD;
      analyzed the structural retinal parameters (ganglion cell complex and retinal nerve fiber&#xD;
      layer), using optical coherence tomography (OCT) in these patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Beta Thalassemia is one of the most common genetic hemoglobinopathy characterized by a&#xD;
      defective Î² globulin chain synthesis leading to hemolysis and ineffective erythropoiesis.&#xD;
&#xD;
      The study investigated the changes in retinal and choriocapillaris vascular features using&#xD;
      optical coherence tomography angiography, a novel and noninvasive diagnostic technique that&#xD;
      allows a detailed analysis of retinal and choriocapillaris blood flow.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Actual">February 28, 2020</completion_date>
  <primary_completion_date type="Actual">February 25, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The measurements of retinal and choriocapillaris features in patients with Beta Thalassemia, using optical coherence tomography angiography.</measure>
    <time_frame>Four months</time_frame>
    <description>The parameters analyzed by optical coherence tomography angiography were: retinal and choriocapillaris vessel density</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The measurements of retinal structural parameters in patients with Beta Thalassemia, using optical coherence tomography.</measure>
    <time_frame>Four months</time_frame>
    <description>The parameters analyzed by optical coherence tomography were: ganglion cell complex and retinal nerve fiber layer</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">82</enrollment>
  <condition>Thalassemia</condition>
  <arm_group>
    <arm_group_label>Patients with Beta Thalassemia</arm_group_label>
    <description>Patients with previous diagnosis of Beta Thalassemia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <description>Healthy fellow eyes without actual and previous ocular trauma</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Optical coherence tomography angiography</intervention_name>
    <description>Each subject underwent Optical coherence tomography angiography (a non-invasive, fast, diagnostic imaging technique)</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Patients with Beta Thalassemia</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The participans were older than 35 years with diagnosis of Beta Thalassemia. They did not&#xD;
        present other ophthalmological diseases.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age older than 35 years&#xD;
&#xD;
          -  diagnosis of Beta Thalassemia&#xD;
&#xD;
          -  absence of previous ocular surgery, congenital eye disease, high myopia (&gt;6 dioptres),&#xD;
             actual or previous diagnosis of glaucoma, optic disc anomaly, macular or vitreoretinal&#xD;
             diseases.&#xD;
&#xD;
          -  absence of significant lens opacities, low-quality OCT and OCT-A images.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age older than 50 years&#xD;
&#xD;
          -  absence of diagnosis of Beta Thalassemia&#xD;
&#xD;
          -  presence of previous ocular surgery, congenital eye disease, high myopia (&gt;6&#xD;
             dioptres), actual or previous diagnosis of glaucoma, optic disc anomaly, macular or&#xD;
             vitreoretinal diseases.&#xD;
&#xD;
          -  presence of significant lens opacities, low-quality OCT and OCT-A images.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Naples &quot;Federico II&quot;</name>
      <address>
        <city>Naples</city>
        <zip>80100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 3, 2020</study_first_submitted>
  <study_first_submitted_qc>October 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2020</study_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federico II University</investigator_affiliation>
    <investigator_full_name>Gilda Cennamo</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>beta-Thalassemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

